Journals / Meandros Medical And Dental Journal / 2026 / Volume: 26 Issue: 4

The Impact of Lymphovascular Invasion on Prognosis and Survival in Operated Lung Cancer Patients

Opere Akciğer Kanserli Hastalarda Lenfovasküler İnvazyon Varlığının Prognoz ve Sağkalım Üzerine Etkisi

Salih Çokpınar(AYDIN ADNAN MENDERES ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-1251-0759
Nesibe Kahraman Çetin(AYDIN ADNAN MENDERES ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, TIBBİ PATOLOJİ ANABİLİM DALI)0000-0002-4549-1670
Serdar Şen(AYDIN ADNAN MENDERES ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7061-7901
Nilgün Kanlıoğlu(AYDIN ADNAN MENDERES ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0002-7116-4905
Selda Şen(AYDIN ADNAN MENDERES ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0001-7452-9888
İmran Kurt Omurlu(AYDIN ADNAN MENDERES ÜNİVERSİTESİ, TIP FAKÜLTESİ)0000-0003-2887-6656
Pages
—
Publication Date
2025-12-25
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We believe that the presence of LVI in the tumor can be used as a parameter to offer adjuvant therapies to patients with resected non-small cell lung cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Despite many improvements in imaging techniques and oncologic therapy in recent years, lung cancer remains the leading cause of cancer-related mortality worldwide.
📊
Key Findings & Data:Materials and Methods: 111 patients who underwent surgical resection for lung cancer in a fourteen-year period were included in the study.
💡
Conclusion & Impact:We believe that the presence of LVI in the tumor can be used as a parameter to offer adjuvant therapies to patients with resected non-small cell lung cancer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Non-small cell lung cancer · Surgical resection · Lymphovascular invasion

Abstract

Objective: Despite many improvements in imaging techniques and oncologic therapy in recent years, lung cancer remains the leading cause of cancer-related mortality worldwide. Currently, the only curative treatment for lung cancer is still lung resection. However, patients who undergo surgery in the early stages of lung cancer are still at risk of recurrence or metastasis. The pathologic stage after resection is the most important prognostic factor for survival and forms the basis of guideline recommendations for adjuvant therapies. Lymphovascular invasion(LVI), one of the parameters evaluated in pathological examination, is a key entity in terms of tumor dissemination and carries critical importance in influencing disease recurrence, lymph node metastasis, distant metastasis and disease-free survival. In this study, we investigated the relationship between LVI and clinical and histopathologic parameters in patients who underwent lung resection for primary lung cancer and evaluated its effect on prognosis and survival. Materials and Methods: 111 patients who underwent surgical resection for lung cancer in a fourteen-year period were included in the study. Histopathological examinations of the resected surgical specimens were performed and all histopathological parameters were recorded. Data concerning demographic characteristics and life expectancy of the patients were obtained from archival records. Results: Majority of the study population of 111 cases mostly(95.5%) consisted of male patients with a mean(±SD) age of 62.24±8.44 years. Approximately 13% of the patients were still alive. Most frequently(63.06%) lobectomies were.performed. LVI was detected at a higher rate in patients with squamous cell carcinomas(p=0.005). The incidence of LVI increased as both T factor(p=0.029) and N factor(p=0.000) increased. Regardless of tumor type, LVI was more frequenty seen in advanced stages of the disease(p=0.005). There was no significant correlation between LVI and survival(p=0.916). Conclusion: LVI is the first step of tumor invasion and metastasis and correlates with recurrence and survival rates for some cancer types such as gynecologic and head and neck tumors. Therefore, LVI is a promising area to be studied in future clinical trials on lung cancer. We believe that the presence of LVI in the tumor can be used as a parameter to offer adjuvant therapies to patients with resected non-small cell lung cancer.

Özet

Amaç: Günümüzde akciğer kanserinin tek küratif tedavisi hala akciğer rezeksiyonudur. Ancak erken evrelerde cerrahi yapılan hastalar hala nüks veya metastaz açısından risk altındadır. Bu durumun, tanı ve ameliyattan önce lenfovasküler sisteme geçmiş kanser hücrelerinin varlığından kaynaklanıyor olabileceği düşünülmektedir. Patolojik incelemede değerlendirilen parametrelerden biri olan Lenfovasküler invazyon (LVI), tümör disseminasyonu açısından kilit bir olaydır ve lenf nodu metastazı, rekürrens, uzak metastaz ve hastalıksız yaşam süresini etkilemektedir. Bu çalışmada, ondört yıllık süreç içerisinde primer akciğer kanseri nedeniyle akciğer rezeksiyonu yapılan hastalarda, LVI’nun klinik ve histopatolojik parametrelerle ilişkisini araştırarak, bunun prognoz ve sağkalıma etkisini değerlendirdik. Materyal ve metod: Kliniğimizde ondört yıllık süreçte akciğer kanseri nedeniyle anatomik rezeksiyon yapılmış 111 hasta çalışmaya alındı. Materyallerin patolojik incelemeleri yapılarak değerlendirilen tüm histopatolojik parametreler kaydedildi. Hastaların demografik verileri ve yaşam süreleri arşiv kayıtlarından elde edildi. Bulgular: 111 hastanın %95,5’i erkek olup, yaş ortalaması 62,24±8,44’dü. Olguların yaklaşık %13’ü hayattaydı. Anatomik rezeksiyonların %63.06’sı lobektomiydi. Skuamöz hücreli karsinomlarda LVI daha fazlaydı (p=0.005). Hem T faktörü (p=0,029), hem de N faktörü (p=0,000) arttıkça LVI görülme sıklığının arttığı saptandı. Tümör tipinden bağımsız olarak hastaların evresi arttıkça LVI’un daha sık görüldüğü izlendi (p=0,005). LVI ile sağkalım arasında anlamlı ilişki saptanmadı (p=0.916). Sonuç: LVI tümör yayılımı ve metastazın ilk adımı olup, jinekolojik ve baş-boyun tümörleri gibi bazı kanser tipleri için rekürrens ve sağkalım ile korelasyon gösterir. Bu nedenle LVI akciğer kanseri için gelecekte klinik çalışmalarda çalışılacak umut vaad eden bir alandır. Tümörde LVI varlığının, rezeke edilmiş akciğer kanserli hastalara adjuvan tedaviler sunmak için bir parametre olarak kullanılabileceğine inanıyoruz.

🔖

Cite This Article

Çokpınar, S., Çetin, N. K., Şen, S., Kanlıoğlu, N., Şen, S., Omurlu, İ. K., *, N. K. Ç. (2025). The Impact of Lymphovascular Invasion on Prognosis and Survival in Operated Lung Cancer Patients. Meandros Medical And Dental Journal, Volume: 26 Issue: 4. https://doi.org/10.69601/meandrosmdj.1709419

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (35)

  1. Cokpinar S, Erdogdu IH, Orenay-Boyacioglu S, Boyacioglu, O, Kahraman-Cetin N, Meteoglu I. PIK3CA Mutations and Co-Mutations in Operated Non-Small Cell Lung Carcinoma. J. Clin. Med. 2024;13:7472.
  2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, et al. Cancer statistics. CA: Cancer J Clin. 2006;56(2):106-130.
  3. Woodward RM, Brown ML, Stewart ST, Cronin KA, Cutler DM. The value of medical interventions for lung cancer in the elderly: results from SEER-CMHSF. Cancer. 2007;110:2511-2518.
  4. Okiror L, Harling L, Toufektzian L, King J, Routledge T, Harrison-Phipps K, et al. Prognostic factors including lymphovascular invasion on survival for resected non–small cell lung cancer. J Thorac Cardiovasc Surg. 2018;156(2):785-793.
  5. Lin M, Zhao X, Huang H, Lin H, Li K. A nomogram for predicting lymphovascular invasion in lung adenocarcinoma: a retrospective study. BMC Pulm Med. 2024;24(1):588.
  6. Nie P, Yang G, Wang N, Yan L, Miao W, Duan Y, et al. Additional value of metabolic parameters to PET/CT-based radiomics nomogram in predicting lymphovascular invasion and outcome in lung adenocarcinoma. Eur J Nucl Med Mol Imaging. 2021;48(1):217–230.
  7. Brunelli A, Charloux A, Bolliger CT, Rocca G, Sculier JP, Varela G, et al. The European Respiratory Society and European Society of Thoracic Surgeons clinical guidelines for evaluating fitness for radical treatment (surgery and chemoradiotherapy) in patients with lung cancer. Eur J Cardiothorac Surg. 2009;36:181-184.
  8. Byrd DR, Brookland R K, Washington MK, Gershenwald JE, Compton CC, Hess KR, et al. (2017). AJCC cancer staging manual 8th ed. (Vol. 1024). Amin MB, Edge SB, Greene FL (Eds.). New York: Springer.
  9. Kinoshita T, Ohtsuka T, Yotsukura M, Asakura K, Goto T, Kamiyama I, et al. Prognostic impact of preoperative tumor marker levels and lymphovascular invasion in pathological stage I adenocarcinoma and squamous cell carcinoma of the lung. J Thorac Oncol. 2015;10:619-628.
  10. Chen YY, Huang TW, Tsai WC, Lin LF, Cheng JB, Lee SC, et al. Lymphovascular space invasion and tumor differentiation are predictors for postoperative recurrence in patients with pathological stage I nonsmall cell lung cancer. J Chin Med Assoc. 2014;77:416-421.
  11. Keys HM, Roberts JA, Brunetto VL, Zaino RJ, Spirtos NM, Bloss JD, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a gynecologic oncology group study. Gynecol Oncol. 2004;92:744-751.
  12. Huang TY, Hsu LP, Wen YH, Huang TT, Chou YF, Lee CF, et al. Predictors of locoregional recurrence in early stage oral cavity cancer with free surgical margins. Oral Oncol. 2010;46:49-55.
  13. Li Z, Yu Y, Lu J, Luo Q, Wu C, Liao M, et al. Analysis of the T descriptors and other prognosis factors in pathologic stage I non-small cell lung cancer in China. J Thorac Oncol. 2009;4(6):702-709.
  14. WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon (France): International Agency for Research on Cancer (IARC); Lyon, France, 2021, pp. 19-84. (WHO classification of tumours series, 5th ed.; vol. 5). https://publications.iarc.fr/595.
  15. Schneider F, Butnor K, Beasley MB, Dacic S. Protocol for the examination of resection specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. College of American Pathologists (CAP); December 2024.Version 5.0.0.0 College of American Pathologists.
  16. Zhang X, Ma L, Xue M, Sun Y, Wang Z. Advances in lymphatic metastasis of non-small cell lung cancer. Cell Commun and Signal. 2024;22(1):201.
  17. Göksel T. Tedavi kararı ve prognoz. Akciğer tümörleri. Solunum Hastalıkları Cilt 2. 2010; 7.1.2.3:1423-1429.
  18. Bünül İ, Dağoğlu N, Oral EN. Küçük hücreli dışı akciğer kanserinde postoperatif radyoterapi. Turkiye Klinikleri Radiation Oncology-Special Topics. 2021;7.4:29-32.
  19. Kalaycı G, Dilege Ş, Toker A, Tanju S, Ziyade S, Bayrak Y. Sleeve reseksiyonları: 77 olgunun değerlendirilmesi. Türk Göğüs Kalp Damar Cer Derg 2005;13(4):397-402.
  20. Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa, A, et al. Effect of tumor size on prognosis in patients with non–small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg. 2005;129(1):87-93.
  21. Albain KS, Rusch VW, Crowley JJ, Rice TW, Turrisi AT, Weick JK, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol. 1995;13(8):1880-1892.
  22. Özkan B, Kaba E, Erus S, Kapdağli M, Ziyade S, Tanju S, et al. Primer Akciğer Kanserinde Neoadjuvan Tedavi Uygulanmış Hastalarda Akciğer Rezeksiyonları: İlk 90 Olgunun Güncel Bilgilerimizle Gözden Geçirilmesi. Journal of Istanbul Faculty of Medicine/İstanbul Tıp Fakültesi Dergisi. 2016;79(1).
  23. Lee JG, Cho BC, Bae MK, Lee CY, Park IK, Kim DJ, et al. Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. Lung Cancer. 2009;63(1):106-110.
  24. Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209-249.
  25. Bayır D, Yetişyiğit, T. Metastatik Küçük Hücreli Dışı Akciğer Kanserli Hastaların Demografik Özelliklerinin Değerlendirilmesi. Namık Kemal Tıp Dergisi. 2017;5(1):1-6.
  26. Cheng L, Alexander R, MacLennan GT, Cummings OW, Monironi R, Lopez-Beltran A et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012;25(3):347-369.
  27. Sanchez-Salcedo P, Berto J, de-Torres JP, Campo A, Alcaide AB, Bastarrika G, et al. Lung cancer screening: fourteen year experience of the Pamplona early detection program (P-IELCAP). Arch Bronconeumol (English Edition). 2015;51(4):169-176.
  28. Lortet-Tieulent J, Soerjomataram I, Ferlay J, Rutherford M, Weiderpass E Bray F. International trends in lung cancer incidence by histological subtype: Adenocarcinoma stabilizing in men but still increasing in women. Lung Cancer 2014;84(1):13–22.
  29. Wahbah M, Boroumand N, Castro C, El-Zeky F, Eltorky M. Changing trends in the distribution of the histologic types of lung cancer: a review of 4,439 cases. Ann Diagn Pathol. 2007;11:89-96.
  30. Goksel T, Akkoclu A. Turkish Thoracic Society, Lung And Pleural Malignancies Study Group. Pattern Of Lung Cancer In Turkey, 1994-1998. Respiration. 2002;69:207-210.
  31. Gabor S, Renner H, Popper H, Anegg U, Sankin O, Matzi V, et al. Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer. Eur J Cardiothorac Surg. 2004;25:439-442.
  32. Kawachi R, Tsukada H, Nakazato Y, Takei H, Furuyashiki G, Koshiishi Y, et al. Early recurrence after surgical resection in patients with pathological stage I non-small cell lung cancer. Thorac Cardiovasc Surg. 2009;57(8):472-475.
  33. Gao YS, Xing XZ, Shao K, Feng XL, He J. Analysis of prognostic factors in 1826 patients with completely resected non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi. 2008;30(2):134-137.
  34. Yanagawa N, Shiono S, Abiko M, Ogata SY, Sato T, Tamura, G. Prognostic impact and initial recurrence site of lymphovascular and visceral pleural invasion in surgically resected stage I non-small-cell lung carcinoma. Eur J Cardiothorac Surg. 2013;44(3):e200-e206.
  35. Yilmaz A, Duyar SS, Cakir E, Aydin E, Demirag F, Karakaya J, et al. Clinical impact of visceral pleural, lymphovascular and perineural invasion in completely resected non-small cell lung cancer. Eur J Cardiothorac Surg. 2011;40(3):664-670.